J&J buys Aragon’s prostate cancer arm


Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson. The deal covers Aragon’s androgen receptor antagonist programme, including an advanced drug candidate for prostate cancer.

Androgen has spun out the rest of the company to form Seragon Pharmaceuticals, which will develop breast cancer drugs that work by degrading oestrogen receptors.

J&J paid $650 million (£417 million) up front, and will pay up to $350 million more if various milestones are reached. The androgen receptor antagonist programme will be managed by J&J’s subsidiary Janssen.


Related Content

Business roundup

30 June 2011 Business

news image

Industry news, July 2011

Design for life

28 October 2009 Premium contentFeature

news image

A new drug for treating prostate cancer, developed by rational design and currently making its way through clinical trials, c...

Most Commented

Toilet flushes could help power homes

15 April 2014 Research

news image

Transducer converts water motion into energy

How to print a crystal in 3D

17 April 2014 Research

news image

Rather than looking at a crystal on a screen, print it out and hold it in your hand